China biopharma financing rose 26% YoY in March, with VC/PE resilience standing out as the key highlight

Overview

This report tracks biopharma financing trends in China and globally, with a focus on the VC/PE, IPO, and follow-on financing breakdowns for March 2026 and Q1 2026. The core conclusion is that China biopharma total financing continued to ease on a monthly basis, but still improved year over year, with VC/PE financing in particular remaining resilient and potentially supporting a recovery in domestic CRO demand.

Core views

UBS believes the continued strength of China biopharma VC/PE financing is a constructive signal, indicating that capital is still flowing into early-stage biotech companies. Because such companies typically have high R&D outsourcing needs, continued financing momentum could support a further recovery in domestic CRO demand. At the same time, IPO and follow-on financing remain under pressure, with IPOs at zero for a second straight month, although the expanding IPO pipeline provides a foundation for a future rebound in IPO financing.

Analysis framework

The report uses a financing-tracking framework, comparing China and global biopharma financing on a monthly, quarterly, year-over-year, month-over-month, and quarter-over-quarter basis, and decomposes financing sources such as VC/PE, IPO, and secondary/follow-on financing to assess the impact of capital market conditions on the CRO, CDMO, and biotech ecosystem.

Methodology notes

• Financing trackingBiopharma financing component analysis

  Break financing into VC, PE, IPO, and follow-on, and compare YoY, MoM, and QoQ changes.

  This approach is used to identify the structural drivers behind changes in total financing; for example, when VC/PE is stronger than IPO, it may more directly reflect the early-stage biotech financing environment and R&D outsourcing demand.

• Industry demand mappingTransmission from financing momentum to CRO demand

  Improving early-stage biotech financing may support a recovery in CRO demand.

  The report argues that biotech companies usually have high R&D outsourcing needs, so if VC/PE capital inflows persist, they should support domestic CRO demand.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Chinese CRO companies

  Heavily influenced by the domestic early-stage biotech financing environment

  Strengths

  VC/PE financing grew strongly on a YoY basis and remained positive on a MoM basis, which may improve biotech clients' R&D budgets and outsourcing demand.

  Weaknesses

  Total financing has contracted on a MoM basis for three consecutive months, and weak IPO and follow-on financing may constrain funding sources for some companies.

  Comparison

  March 2026 financing remained stronger than in the same period of 2024 and 2023; Q1 2026 financing was 54% above Q1 2019.

  Risks

  If the VC/PE trend cannot be sustained, the CRO demand recovery may be weaker than expected.

• Chinese biotech companies

  Directly affected by VC/PE, IPO, and follow-on financing conditions

  Strengths

  VC/PE capital continues to flow into early-stage biotech companies, and the IPO pipeline is expanding.

  Weaknesses

  No IPOs for the second consecutive month, and follow-on financing declined both YoY and MoM.

  Comparison

  VC/PE performance is clearly stronger than IPO and follow-on financing.

  Risks

  The recovery of the public-market financing window is uncertain, and whether the IPO pipeline can translate into actual financing still needs to be monitored.

• Global CDMO companies

  Influenced by global biopharma financing and demand for new technology formats

  Strengths

  The report says the covered CDMO companies maintain a positive outlook for global demand and are supported by demand for new technology formats and exposure to large global multinational pharma companies.

  Weaknesses

  Global financing fell 10% MoM in March, and segment performance was mixed.

  Comparison

  Global biopharma financing in Q1 2026 rose 95% YoY, while both IPO/secondary and VC/PE also posted YoY growth in the quarter.

  Risks

  Volatility in global financing and lower transaction counts may affect the pace at which demand is realized.

Key data

• China biopharma financing, March 2026RMB 4.4 billionUp 26% YoY and down 34% MoM, marking the third consecutive month of MoM contraction, but still above March 2024 and March 2023 levels.
• China VC/PE financing, March 2026RMB 3.4 billionUp 116% YoY and 1% MoM, the main positive signal highlighted by the report.
• China biopharma financing, Q1 2026Up 107% YoY, down 31% QoQIPO was the main drag, down 88% QoQ and 6% YoY; however, Q1 financing was still 54% above Q1 2019.
• China IPO eventsZero for the second consecutive monthThe IPO pipeline expanded to 99 companies, including 86 H-shares and 13 A-shares, up 7 from the end of February.
• China follow-on financing, March 2026Down 21% YoY, down 68% MoMAside from VC/PE, follow-on financing was relatively weak.
• Global biopharma financing, March 2026US$4.4 billionUp 34% YoY and down 10% MoM; Q1 2026 rose 95% YoY.
• Global IPO/secondary financing, March 2026Up 146% YoY, down 24% MoMThere were five public-market transactions above US$200 million.
• Global VC/PE deal count, March 2026Down 34% YoY, up 55% MoMThe MoM improvement was partly driven by a low base in February; in Q1 2026, global IPO/secondary financing was up 153% YoY and VC/PE financing was up 26% YoY.

Impact & implications

For investors, the message is not a broad-based financing recovery, but rather a structural divergence: VC/PE financing is relatively resilient, which is positive for the early-stage R&D ecosystem and CRO demand; IPO and follow-on financing remain weak, indicating that the public market financing environment has not fully recovered. For global CDMO demand, the report says the covered CDMO companies maintain a positive outlook for global demand and gave promising guidance after 2025 results, supported by demand from new technology formats and exposure to large global multinational pharma companies.

Risks

• Greater-than-expected price cuts in GPO programs such as volume-based procurement.
• Intensifying industry competition.
• Prices for innovative drugs after inclusion in the national reimbursement negotiation come in below expectations.
• China's consumption recovery is slower than expected.
• Regulatory announcements and enforcement are stricter than expected.
• Geopolitical tensions unexpectedly escalate and affect company operations.

What to watch

• Whether China VC/PE financing can continue to maintain strong YoY growth and MoM resilience.
• Whether the 99-company IPO pipeline can translate into actual listings and financing.
• Whether follow-on financing can recover from the March YoY and MoM decline.
• Whether domestic CRO orders and demand rebound as early-stage biotech funding improves.
• The follow-up guidance and realization of demand for new technology formats among global CDMO companies.
• Changes in policy-driven price cuts, reimbursement negotiations, regulation, and geopolitical risks.